A Form 4 filed on September 3, 2026, with the U.S. Securities and Exchange Commission discloses two transactions in Moderna, Inc. common stock by Chief Financial Officer James M. Mock on September 1, 2026.

Key Highlights

  • RSU conversion: 2,475 restricted stock units converted into 2,475 shares of common stock on September 1, 2026, at a price of $0.
  • Shares withheld for taxes: 1,197 shares were withheld at a price of $140.34 per share to satisfy tax withholding obligations connected to the RSU vest.
  • Beneficial ownership after transactions: Mock directly holds 68,282 shares of common stock following the reported transactions.
  • Remaining RSUs: Mock holds 24,755 restricted stock units following the reported derivative transaction.
  • Vesting schedule: 25% of the RSU award vested on March 1, 2026, with the remainder vesting in twelve equal quarterly installments thereafter.

Moderna CFO Mock's RSU Vest and Tax Withholding on September 1, 2026

According to the filing, James M. Mock, Chief Financial Officer of Moderna, Inc. (NASDAQ:MRNA), was party to two transactions in the company's common stock on September 1, 2026. The first was coded "M," reflecting the conversion of 2,475 restricted stock units into an equal number of common shares on a one-for-one basis, as the filing notes restricted stock units convert into common stock on a one-for-one basis. Following that acquisition, Mock's direct beneficial ownership of common stock stood at 69,479 shares.

The second transaction, coded "F," involved the disposal of 1,197 shares at $140.34 per share. The filing states this "represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units." After this withholding, Mock's directly held common stock position was reduced to 68,282 shares.

In the derivative securities table, the filing shows the same 2,475-unit RSU settlement reduced Mock's outstanding restricted stock units to 24,755, held directly. The filing describes the underlying vesting schedule as 25% vesting on March 1, 2026, with the remaining portion vesting in twelve equal quarterly installments thereafter. The Form 4 was signed by James Dillon as attorney-in-fact on September 3, 2026.

What Was Disclosed

The filing reports a scheduled RSU vest of 2,475 shares by Moderna's CFO on September 1, 2026, followed by a tax withholding disposal of 1,197 shares at $140.34, leaving Mock with a direct holding of 68,282 common shares and 24,755 remaining RSUs.